PROBLEM LIST EXPORT
Source: Previous EHR System (MS Center)
Export Date: 2023-12-20
Patient: Christopher Martinez    DOB: 03/30/1979    MRN: 34567123

================================================================================
ACTIVE PROBLEMS
================================================================================
1. Multiple Sclerosis, Relapsing-Remitting (G35)
   - First Documented: 2012-06-18
   - Status: Active
   - Managing Provider: Dr. Amy Nguyen (Neurology/MS)
   - Notes: On ocrelizumab (Ocrevus). EDSS 2.5. 2 relapses in past 5 years.

2. Neurogenic Bladder (N31.9)
   - First Documented: 2018-04-22
   - Status: Active
   - Notes: Urinary urgency/frequency. On oxybutynin.

3. Fatigue, MS-related (G35)
   - First Documented: 2013-08-15
   - Status: Active
   - Notes: On modafinil PRN.

4. Depression (F32.1)
   - First Documented: 2015-11-10
   - Status: Active
   - Notes: MS-associated. On bupropion.

5. Vitamin D Deficiency (E55.9)
   - First Documented: 2012-06-18
   - Status: Active
   - Notes: On high-dose supplementation.

================================================================================
RESOLVED PROBLEMS
================================================================================
1. MS Relapse - Optic Neuritis, left (H46.10)
   - Episode: 2020-08-15 to 2020-09-20
   - Notes: IV steroids. Vision mostly recovered.

2. MS Relapse - Sensory (G35)
   - Episode: 2022-01-10 to 2022-02-15
   - Notes: Left-sided numbness. IV steroids. Resolved.

================================================================================
SURGICAL HISTORY
================================================================================
None

================================================================================
ALLERGIES
================================================================================
1. Interferon beta-1a (Avonex)
   - Reaction: Severe flu-like symptoms, depression worsening
   - Severity: Moderate
   - Notes: Tried early in disease, switched therapies

================================================================================
